10-K: VBI Vaccines Secures Forbearance Agreement Amidst Revenue Shortfall

VBI Vaccines has entered into a forbearance agreement with its lenders following a failure to meet revenue targets, providing a temporary reprieve from exercising remedies.

Summary

• VBI Vaccines has entered into a forbearance agreement with its lenders, K2 HealthVentures LLC, effective November 13, 2023.
• The agreement comes after VBI failed to achieve required revenue for the measurement period ended September 30, 2023.
• The lenders have agreed to temporarily refrain from exercising their rights and remedies related to the specified defaults.
• This forbearance period extends through the Forbearance Expiration Date, which is defined in Schedule 2 of the agreement.
• The forbearance is contingent upon VBI's compliance with the terms and conditions outlined in Schedule 2 and other loan documents.
• The forbearance period will immediately terminate if any other event of default occurs, including a breach of this agreement.
• The agreement includes a general release of the lenders from any claims related to the loan documents up to the date of the agreement.

Sentiment

Score: 3

Explanation: The document indicates a negative situation for VBI due to the revenue shortfall and need for a forbearance agreement. While the agreement provides temporary relief, it also highlights financial challenges and the risk of future defaults. The sentiment is therefore negative.

Positives

• The forbearance agreement provides VBI Vaccines with a temporary reprieve from lender actions following a revenue shortfall.
• The agreement allows VBI to continue operations while addressing the specified defaults.
• The lenders have agreed to forbear from exercising their rights and remedies, indicating a willingness to work with VBI.

Negatives

• The forbearance agreement was triggered by VBI's failure to meet revenue targets, indicating financial challenges.
• The forbearance period is conditional, and any new event of default will immediately terminate the agreement.
• VBI is required to adhere to strict terms and conditions during the forbearance period, including providing regular financial updates.

Risks

• The forbearance period can be terminated immediately if any new event of default occurs, including a breach of the forbearance agreement.
• VBI must adhere to strict terms and conditions during the forbearance period, including providing regular financial updates and adhering to a 13-week cash flow budget.
• Failure to comply with the terms of the forbearance agreement could lead to the lenders exercising their rights and remedies under the loan documents.
• The company's financial situation is precarious, as evidenced by the need for a forbearance agreement due to a revenue shortfall.

Future Outlook

The document does not provide any specific forward-looking statements or guidance, but it implies that VBI needs to improve its financial performance to avoid further defaults.

Management Comments

• Borrowers hereby acknowledge that the Specified Defaults have occurred.

Industry Context

Forbearance agreements are not uncommon in the biotechnology industry, especially for companies that are still in the development or early commercialization phase and may face challenges in meeting financial targets.

Comparison to Industry Standards

• It is difficult to compare this situation to industry standards without knowing the specific financial details of VBI and its peers.
• However, it is not uncommon for biotech companies to face financial challenges and seek forbearance agreements.
• The specific terms and conditions of the forbearance agreement would need to be compared to similar agreements in the industry to assess its favorability.

Stakeholder Impact

• Shareholders face increased risk due to the company's financial challenges.
• Employees may experience uncertainty due to the company's financial situation.
• Lenders are exposed to increased risk due to the company's failure to meet revenue targets.
• Customers may be impacted by potential disruptions to the company's operations.

Next Steps

• VBI must comply with the terms and conditions of the forbearance agreement.
• VBI needs to improve its financial performance to avoid further defaults.
• VBI must provide regular financial updates and adhere to a 13-week cash flow budget.

Key Dates

Keywords

forbearance agreement, VBI Vaccines, K2 HealthVentures LLC, loan agreement, revenue shortfall, default, lenders, financial obligations, specified defaults, forbearance period